Advanced Search
Discover new calcs: choose 1 function + 1 more filter
Examples:
Click here to discover
Pulmonary Embolism
calculators for
Diagnosis
After you diagnose a PE, discover
Pulmonary Embolism
calculators for
Prognosis

    Calc Function

  • Calcs that help predict probability of a diseaseDiagnosis
  • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
  • Disease is diagnosed: prognosticate to guide treatmentPrognosis
  • Numerical inputs and outputsFormula
  • Med treatment and moreTreatment
  • Suggested protocolsAlgorithm

Disease

Select...

Specialty

Select...

Chief Complaint

Select...

Organ System

Select...

Follicular Lymphoma International Prognostic Index (FLIPI)

Estimates overall survival based on clinical information.

Advice

A FLIPI score of 0 to 1 is considered “low risk” with a 10 year overall survival of 70%. A score of 2 is considered “intermediate risk” with a 10 year overall survival of 50%. Finally, a score of ≥ 3 is considered “high risk” with a 10 year overall survival of 35%. Patients with an initial remission duration less than the median progression free survival for a particular treatment regimen and/or with a high FLIPI score are more likely to have a shorter remission duration.

Management

Treatment is varied depending on the stage and tumor burden.

Stages I-II

  • Treatment options include:
    • Involved field radiotherapy (IFRT)
    • Clinical trials
    • Active surveillance

Stages III-IV or Bulky stage II – asymptomatic

  • Treatment options include:
    • Clinical trials
    • Active surveillance

Stages III-IV or Bulky Stage II – with GELF/BNLI risk factors or high-risk FLIPI score

  • Treatment options include:
  • Rituximab + cyclophosphamide, vincristine, doxorubicin, prednisone
  • Rituximab alone
  • Bendamustine + rituximab
  • Rituximab + cyclophosphamide, vincristine, prednisone
  • Clinical trials

Critical Actions

  • There is continued controversy around when and how to treat follicular lymphoma, including in patients with relapsed/refractory disease. Questions to consider when making treatment decisions:
    • When to initiate therapy versus active surveillance
    • Deciding amongst various treatment options
    • Balancing efficacy and toxicities of treatment options
    • Determining what constitutes a complete response/endpoint of treatment
  • Finally, with follicular lymphoma, a provider should be aware of transformation to diffuse large B-cell lymphoma, which is a more aggressive disease and would require prompt treatment.